Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology

Circulation Research

Volumn 104, Issue 1, 2009, Pages 124-133

  Wilkinson Berka, Jennifer L ^a   Tan, Genevieve ^a   Jaworski, Kassie ^a   Miller, Antonia G ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Aldosterone; Angiogenesis; Inflammation; Mineralocorticoid receptor; Retina

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 2; ALDOSTERONE; ALDOSTERONE SYNTHASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; OXYGEN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; SPIRONOLACTONE; ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANGIOGENESIS INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CYTOKINE; DRUG DERIVATIVE; EYE PROTEIN; NOX4 PROTEIN, RAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SODIUM CHLORIDE; TETRAZOLE DERIVATIVE; VALINE; VALSARTAN; VASCULAR ENDOTHELIAL GROWTH FACTOR A, RAT; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; COW; ENDOTHELIUM CELL; INFLAMMATION; LEUKOSTASIS; MOLECULAR MECHANICS; NONHUMAN; PERICYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RECEPTOR BLOCKING; RETINA CELL; RETINITIS; RETINOPATHY; VASCULAR DISEASE; ANIMAL; BIOSYNTHESIS; CATTLE; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETINA VASCULITIS; SPRAGUE DAWLEY RAT;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANGIOGENESIS INHIBITORS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CATTLE; CELLS, CULTURED; CYTOKINES; ENDOTHELIAL CELLS; EYE PROTEINS; GLUCOSEPHOSPHATE DEHYDROGENASE; LEUKOSTASIS; NADPH OXIDASE; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; OXYGEN; PERICYTES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ALDOSTERONE; RENIN-ANGIOTENSIN SYSTEM; RETINAL VASCULITIS; SODIUM CHLORIDE; SPIRONOLACTONE; TETRAZOLES; VALINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59649118170     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.108.176008     Document Type: Article

References (42)

1. Chen J, Smith LE. Retinopathy of prematurity. Angiogenesis. 2007;10: 133-140.
2. Essex RW, Carden SM, Elder JE. Two-year results of laser treatment for retinopathy of prematurity at a single neonatal intensive care unit. Clin Exp Ophthalmol. 2005;33:390-394.
3. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH, Bilous R, Sjolie AK; DIRECT Programme Study Group. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008;372:1394-1402.
4. Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH, Bilous R, Chaturvedi N; DIRECT Programme Study Group. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008;372: 1385-1393.
5. Danser AH, van den Dorpel MA, Deinum J, Derkx FH, Franken AA, Peperkamp E, de Jong PT, Schalekamp MA. Renin, prorenin, and immu-noreactive renin in vitreous fluid from eyes with and without diabetic retinopathy. J Clin Endocrinol Metab. 1989;68:160-167.
6. Berka JL, Stubbs AJ, Wang DZ, DiNicolantonio R, Alcorn D, Campbell DJ, Skinner SL. Renin-containing Muller cells of the retina display endocrine features. Invest Ophthalmol Vis Sci. 1995;36:1450-1458.
7. Sarlos S, Rizkalla B, Moravski CJ, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction between the angiotensin type 2 receptor, VEGF, and angiopoietin. Am J Pathol. 2003; 163:879-887.
8. Moravski CJ, Kelly DJ, Cooper ME, Gilbert RE, Bertram JF, Shahinfar S, Skinner SL, Wilkinson-Berka JL. Retinal neovascularization is prevented by blockade of the renin-angiotensin system. Hypertension. 2000; 36:1099-1104.
9. Wilkinson-Berka JL, Tan G, Jaworski K, Ninkovic S. Valsartan but not atenolol improves vascular pathology in diabetic Ren-2 rat retina. Am J Hypertens. 2007;20:423-430.
10. Nagai N, Izumi-Nagai K, Oike Y, Koto T, Satofuka S, Ozawa Y, Yamashiro K, Inoue M, Tsubota K, Umezawa K, Ishida S. Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-KB pathway. Invest Ophthalmol Vis Sci. 2007;48:4342-4350.
11. Phipps JA, Wilkinson-Berka JL, Fletcher EL. Retinal dysfunction in diabetic Ren-2 rats is ameliorated by treatment with valsartan but not atenolol. Invest Ophthalmol Vis Sci. 2007;48:927-934.
12. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998;351: 28-31.
13. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology. 2002;143: 4828-4836.
14. Hatakeyama H, Miyamori I, Fujita T, Takeda Y, Takeda R, Yamamoto H. Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. J Biol Chem. 1994;269: 24316-24320.
15. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med. 2007; 13:189-197.
16. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29:13-21.
17. Funck RC, Wilke A, Rupp H, Brilla CG. Regulation and role of myocardial collagen matrix remodeling in hypertensive heart disease. Adv Exp Med Biol. 1997;432:35-44.
18. Harada E, Yoshimura M, Yasue H, Nakagawa O. Nakagawa M, Harada M, Mizuno Y, Nakayama M, Shimasaki Y, Ito T, Nakamura S, Kuwahara K, Saito Y, Nakao K, Ogawa H. Aldosterone induces angiotensin-converting-enzyme gene expression in cultured neonatal rat cardiocytes. Circulation. 2001;104:137-139.
19. Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C. Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension. 1999; 33:981-986.
20. Pitt B, Williams G, Remme W, Martinez F, Lopez-Sendon J, Zannad F, Neaton J, Roniker B, Hurley S, Burns D, Bittman R, Kleiman J. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study. Cardiovasc Drugs Ther. 2001;15:79-87.
21. Sato A, Saruta T, Funder JW. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection. Hypertens Res. 2006;29:211-216.
22. Penn JS, Henry MM, Wall PT, Tolman BL. The range of PaO2 variation determines the severity of oxygen-induced retinopathy in newborn rats. Invest Ophthalmol Vis Sci. 1995;36:2063-2070.
23. Yoshida S, Yoshida A, Ishibashi T, Elner SG, Elner VM. Role of MCP-1 and MIP-1a in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol. 2003;73:137-144.
24. Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology. 2000;141:1901-1904.
25. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, Swynghedauw B, Delcayre C. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem. 1998;273:4883-4891.
26. Sun Y, Zhang J, Lu L, Chen S, Quinn MT, Weber KT. Aldosterone-induced inflammation in the rat heart: role of oxidative stress. Am J Pathol. 2002;161:1773-1781.
27. Ishida S, Yamashiro K, Usui T, Kaji Y, Ogura Y, Hida T, Honda Y, Oguchi Y, Adamis AP. Leukocytes mediate retinal vascular remodeling during development and vaso-obliteration in disease. Nat Med. 2003;9: 781-788.
28. Jiang F, Zhang G, Hashimoto I, Kumar BS, Bortolotto S, Morrison WA, Dusting GJ. Neovascularization in an arterio-venous loop-containing tissue engineering chamber: role of NADPH oxidase. J Cell Mol Med. 2008;12:2062-2072.
29. Bernini GP, Moretti A, Bonadio AG, Menicagli M, Viacava P, Naccarato AG, Iacconi P, Miccoli P, Salvetti A. Angiogenesis in human normal and pathologic adrenal cortex. J Clin Endocrinol Metab. 2002;87:4961-4965.
30. Michel F, Ambroisine ML, Duriez M, Delcayre C, Levy BI, Silvestre JS. Aldosterone enhances ischemia-induced neovascularization through angiotensin II-dependent pathway. Circulation. 2004;109: 1933-1937.
31. Klauber N, Browne F, Anand-Apte B, D'Amato RJ. New activity of spironolactone. Inhibition of angiogenesis in vitro and in vivo. Circulation. 1996;94:2566-2571.
32. Knott RM, Robertson M, Muckersie E, Folefac VA, Fairhurst FE, Wileman SM. Forrester JV. A model system for the study of human retinal angiogenesis: activation of monocytes and endothelial cells and the association with the expression of the monocarboxylate transporter type 1 (MCT-1). Diabetologia. 1999;42:870-877.
33. Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG. Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int. 2003;63:1791-1800.
34. Caprio M, Newfell BG, la Sala A, Baur W, Fabbri A, Rosano G, Mendelsohn ME, Jaffe IZ. Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res. 2008; 108:1357-1367.
35. Goede V, Brogelli L, Ziche M, Augustin HG. Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer. 1999; 82:765-770.
36. Griendling KK. NADPH oxidases: new regulators of old functions. Antioxid Redox Signal. 2006;8:1443-1445.
37. Mittal M, Roth M, Konig P, Hofmann S, Dony E, Goyal P, Selbitz AC, Schermuly RT, Ghofrani HA, Kwapiszewska G, Kummer W, Klepetko W, Hoda MA, Fink L, Hanze J, Seeger W, Grimminger F, Schmidt HH, Weissmann N. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res. 2007; 101:258-267.
38. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karu-parthi PR, Qazi M, Morris EM, Cooper SA, Link CD, Stump C, Hay M, Ferrario C, Sowers JR. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology. 2007;148: 3773-3780.
39. Golestaneh N, Picaud S, Mirshahi M. The mineralocorticoid receptor in rodent retina: ontogeny and molecular identity. Mol Vis. 2002;8:221-225.
40. Odermatt A, Arnold P, Frey FJ. The intracellular localization of the mineralocorticoid receptor is regulated by 11/3-hydroxysteroid dehydrogenase type 2. J Biol Chem. 2001;276:28484-28492.
41. Rogacz S, Williams GH, Hollenberg NK. Time course of enhanced adrenal responsiveness to angiotensin on a low salt diet. Hypertension. 1990;15:376-380.
42. Marney AM, Brown NJ. Aldosterone and end-organ damage. Clin Sci (Lond). 2007;113:267-278.